The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

Columnist Dagmar Munn has a Santa wish list for her outings over the holidays: accessible restrooms and good cutlery among ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

Columnist Kristin Neva recognizes the distinction between being thankful "in" a bad situation rather than "for" a bad situation.

RAG-21, a therapy Ractigen Therapeutics is developing for amyotrophic lateral sclerosis (ALS) linked to mutations in the FUS gene, has been awarded orphan drug status by the U.S. Food and Drug ...